US 12,110,341 B2
Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
Reed J. Harris, San Mateo, CA (US); and Paul A. Motchnik, Belmont, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Apr. 19, 2024, as Appl. No. 18/640,824.
Application 18/640,824 is a division of application No. 18/166,994, filed on Feb. 9, 2023.
Application 18/166,994 is a division of application No. 17/815,535, filed on Jul. 27, 2022, granted, now 11,597,776, issued on Mar. 3, 2023.
Application 17/815,535 is a division of application No. 16/503,364, filed on Jul. 3, 2019, granted, now 11,414,498, issued on Aug. 16, 2022.
Application 16/503,364 is a division of application No. 15/450,509, filed on Mar. 6, 2017, abandoned.
Application 14/162,255 is a division of application No. 12/361,180, filed on Jan. 28, 2009, granted, now 8,652,474, issued on Feb. 18, 2014.
Application 15/450,509 is a continuation of application No. 14/162,255, filed on Jan. 23, 2014, abandoned.
Claims priority of provisional application 61/024,825, filed on Jan. 30, 2008.
Prior Publication US 2024/0262932 A1, Aug. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/32 (2006.01); A61K 39/00 (2006.01); C07K 1/18 (2006.01); C07K 16/06 (2006.01); C07K 16/28 (2006.01); G01N 27/447 (2006.01); G01N 30/02 (2006.01)
CPC C07K 16/32 (2013.01) [C07K 1/18 (2013.01); C07K 16/065 (2013.01); C07K 16/2863 (2013.01); C07K 16/2896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/76 (2013.01); G01N 27/447 (2013.01); G01N 30/02 (2013.01); G01N 2030/027 (2013.01)] 30 Claims
 
1. A method of treating HER2 positive cancer in a patient comprising administering a pharmaceutical formulation to the patient in an amount effective to treat the cancer, wherein the pharmaceutical formulation comprises:
(i) a composition comprising:
(a) a main species HER2 antibody comprising light chain and heavy chain amino acid sequences set forth in SEQ ID Nos. 15 and 16, respectively; and
(b) acidic variants of the main species antibody, comprising a disulfide reduced variant, and:
(ii) a pharmaceutically acceptable carrier.